University of Brasilia, Institute of Biological Sciences, Department of Physiological Sciences, Brasilia-DF, 70910-900, Brazil.
University of Brasilia, Institute of Biological Sciences, Department of Physiological Sciences, Brasilia-DF, 70910-900, Brazil.
Reprod Biomed Online. 2023 Oct;47(4):103234. doi: 10.1016/j.rbmo.2023.05.006. Epub 2023 May 14.
Is the optimal timing for administering erythropoietin to minimize ischaemic injury in ovarian tissue transplantation before ovary removal for cryopreservation and subsequent transplantation or after transplantation?
Thirty Swiss mice (nu/nu) were divided into three groups: treatment control group (n = 10); erythropoietin before harvesting group (EPO-BH) (n = 10) and erythropoietin after transplantation group (EPO-AT) (n = 10). Animals underwent bilateral ovariohysterectomy and their hemiovaries were cryopreserved by slow freezing. At the same time, previously cryopreserved hemiovaries were transplanted subcutaneously in the dorsal region. Erythropoietin (250 IU/kg) and sterile 0.9% saline solution were administered every 12/12 h over 5 consecutive days in the EPO-AT and EPO-BH groups, respectively.
Administration of erythropoietin in the EPO-AT group improved the viability of ovarian follicles, reducing degeneration and increasing the number of morphologically normal growing follicles at 14 days after transplantation compared with the EPO-BH group (P = 0.002). This group also showed higher percentages of proliferative follicles at 7 days after transplantation (P ≤ 0.03), increased blood vessel count (P ≤ 0.03) and greater tissue area occupied by blood vessels at days 7 and 14 after transplantation (P ≤ 0.03), compared with hormone administration before cryopreservation (EPO-BH group) and the treatment control group. Additionally, treatment with erythropoietin before or after transplantation reduced fibrotic areas at 7 days after transplantation (P = 0.004).
Erythropoietin treatment after transplantation reduced ischaemic damage in transplanted ovarian tissue, increased angiogenesis, maintenance of ovarian follicle proliferation and reduced fibrosis areas in the grafted tissue.
在为卵巢组织冷冻保存和随后的移植而切除卵巢之前或之后，给予促红细胞生成素以最小化卵巢组织移植中的缺血性损伤的最佳时机是什么？
将 30 只瑞士小鼠（nu/nu）分为三组：治疗对照组（n=10）；促红细胞生成素预处理组（EPO-BH）（n=10）和移植后促红细胞生成素组（EPO-AT）（n=10）。动物接受双侧卵巢子宫切除术，其半卵巢通过慢速冷冻保存。同时，以前冷冻保存的半卵巢被皮下移植到背部区域。EPO-AT 和 EPO-BH 组分别在连续 5 天内，每 12/12 小时给予促红细胞生成素（250IU/kg）和无菌 0.9%生理盐水。
EPO-AT 组给予促红细胞生成素可改善卵巢卵泡的活力，与 EPO-BH 组相比，在移植后 14 天减少退化并增加形态正常生长的卵泡数量（P=0.002）。与冷冻保存前（EPO-BH 组）和治疗对照组相比，该组在移植后 7 天还显示出更高比例的增殖卵泡（P≤0.03）、增加的血管计数（P≤0.03）和移植后 7 天和 14 天血管组织面积增加（P≤0.03）。此外，在移植前后给予促红细胞生成素可减少移植后 7 天的纤维化区域（P=0.004）。
移植后给予促红细胞生成素可减少移植卵巢组织的缺血性损伤，增加血管生成，维持卵巢卵泡增殖并减少移植物中的纤维化区域。
